CD123 targeted CAR-NK cells vs Pivekimab Sunirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD123 · full Acute Myeloid Leukemia pipeline
CD123 targeted CAR-NK cells
Developed by Chongqing Precision Biotech Co., Ltd
NCT06006403 · Phase 1/2 · completed
This was a non-randomized, open-label study with no comparator and only five participants. Its primary outcomes included safety and objective response rate, but results are not posted, so whether the primary outcomes were met cannot be determined.
Next expected readout: June 2027 · NCT06690827 (registry estimate)
No aligned efficacy figure on record for this race.
Pivekimab Sunirine · Decnupaz
Marketed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT04086264 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Acute Myeloid Leukemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | CD123 targeted CAR-NK cells | Pivekimab Sunirine |
|---|---|---|
| OS, median | —Not reported | —Trial running · NCT07581002 |
| Complete remission | —Not reported | —Trial running · NCT07581002 |
| Event-free survival, median | —Not reported | —Trial running · NCT07581002 |
| Duration of response, median | —Not reported | —Trial running · NCT07581002 |
OS, median
- CD123 targeted CAR-NK cells
- —Not reported
- Pivekimab Sunirine
- —Trial running · NCT07581002
Complete remission
- CD123 targeted CAR-NK cells
- —Not reported
- Pivekimab Sunirine
- —Trial running · NCT07581002
Event-free survival, median
- CD123 targeted CAR-NK cells
- —Not reported
- Pivekimab Sunirine
- —Trial running · NCT07581002
Duration of response, median
- CD123 targeted CAR-NK cells
- —Not reported
- Pivekimab Sunirine
- —Trial running · NCT07581002
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
CD123 targeted CAR-NK cells: no structured comparison results are available for Acute Myeloid Leukemia.
Pivekimab Sunirine: no structured comparison results are available for Acute Myeloid Leukemia.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CD123 targeted CAR-NK cells's landscape · Pivekimab Sunirine's landscape